This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Arrhythmia Research Technology, Inc., through its subsidiary, Micron Products, Inc., operates as a contract manufacturing organization that produces medical device technologies requiring precision machining and injection molding in the United States, Canada, Asia, Europe, and internationally.View HRT key stats
Arrhythmia Research Technology - HRT - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Arrhythmia Research Technology as a
Sell with a ratings score of D+.
Report Snippet: We rate ARRHYTHMIA RESEARCH TECH (HRT) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins.